Aristotle Capital Boston LLC Sells 118,358 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Aristotle Capital Boston LLC lessened its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 9.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,075,868 shares of the specialty pharmaceutical company's stock after selling 118,358 shares during the quarter. Supernus Pharmaceuticals makes up about 1.4% of Aristotle Capital Boston LLC's investment portfolio, making the stock its 20th largest position. Aristotle Capital Boston LLC owned 1.95% of Supernus Pharmaceuticals worth $38,903,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of SUPN. Vanguard Group Inc. grew its holdings in shares of Supernus Pharmaceuticals by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 6,150,759 shares of the specialty pharmaceutical company's stock worth $222,411,000 after purchasing an additional 22,852 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Supernus Pharmaceuticals by 1.9% in the fourth quarter. Geode Capital Management LLC now owns 1,510,568 shares of the specialty pharmaceutical company's stock worth $54,633,000 after acquiring an additional 28,517 shares during the last quarter. American Century Companies Inc. grew its stake in shares of Supernus Pharmaceuticals by 9.2% during the fourth quarter. American Century Companies Inc. now owns 1,140,705 shares of the specialty pharmaceutical company's stock valued at $41,248,000 after purchasing an additional 95,777 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in Supernus Pharmaceuticals by 5.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 753,363 shares of the specialty pharmaceutical company's stock valued at $27,242,000 after buying an additional 40,968 shares during the last quarter. Finally, Northern Trust Corp increased its stake in shares of Supernus Pharmaceuticals by 18.3% in the 4th quarter. Northern Trust Corp now owns 717,161 shares of the specialty pharmaceutical company's stock valued at $25,933,000 after buying an additional 110,867 shares during the period.

Insider Activity

In other news, SVP Jonathan Rubin sold 927 shares of the business's stock in a transaction on Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the transaction, the senior vice president now owns 7,853 shares of the company's stock, valued at $307,444.95. The trade was a 10.56 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 9.30% of the stock is currently owned by company insiders.

Supernus Pharmaceuticals Stock Up 2.3 %

NASDAQ SUPN traded up $0.71 on Thursday, reaching $31.65. The company had a trading volume of 204,106 shares, compared to its average volume of 497,203. Supernus Pharmaceuticals, Inc. has a 52 week low of $25.53 and a 52 week high of $40.28. The stock's 50 day moving average is $31.86 and its 200-day moving average is $34.92. The stock has a market cap of $1.77 billion, a price-to-earnings ratio of 29.58 and a beta of 0.74.

Wall Street Analyst Weigh In

Several research firms recently issued reports on SUPN. StockNews.com upgraded Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Thursday, April 17th. Cantor Fitzgerald reiterated a "neutral" rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.